Fibroblast Growth Factors (FGFs) Market Report 2026

The fibroblast growth factors (fgfs) market size has grown strongly in recent years. It will grow from $4.11 billion in 2025 to $4.5 billion in 2026 at a compound annual growth rate (CAGR) of 9.4%. The growth in the historic period can be attributed to expansion of growth factor research programs, increasing clinical trials involving fgfs, rising demand for advanced biologics, growth in oncology drug development, improved recombinant protein manufacturing techniques.

The fibroblast growth factors (fgfs) market size is expected to see strong growth in the next few years. It will grow to $6.37 billion in 2030 at a compound annual growth rate (CAGR) of 9.1%. The growth in the forecast period can be attributed to increasing adoption of fgf-targeted therapies, rising investments in biologics manufacturing, expansion of regenerative medicine pipelines, growing use of precision oncology drugs, increasing regulatory approvals for fgf-based products. Major trends in the forecast period include increasing development of recombinant fgfs, rising use of fgfs in oncology therapies, growing application in wound healing treatments, expansion of fgf-based regenerative medicine, enhanced focus on targeted fgf inhibitors.

The increasing prevalence of chronic diseases is expected to drive the growth of the fibroblast growth factors (FGFs) market in the coming years. Chronic diseases are long-lasting health conditions that develop gradually and often require ongoing medical management. The rise in chronic diseases is partly linked to sedentary lifestyles, as prolonged inactivity and minimal physical exercise elevate the risk of heart disease and diabetes. Fibroblast growth factors (FGFs) aid in chronic disease management by promoting tissue repair and regeneration, making them valuable for treating long-term health conditions. They support the healing process, slow disease progression, and enhance patient outcomes and overall quality of life. For instance, in June 2024, according to the National Health Service, a UK-based government agency, 3,615,330 individuals registered with a general practitioner (GP) were diagnosed with non-diabetic hyperglycemia or pre-diabetes (a condition with elevated blood sugar levels not high enough to be classified as diabetes) in 2023, reflecting an 18% increase from 3,065,825 cases in 2022. Therefore, the growing prevalence of chronic diseases is driving the growth of the fibroblast growth factors (FGFs) market.

Major companies in the fibroblast growth factors (FGFs) market are increasingly focusing on developing innovative solutions, such as synthetic peptide-based alternatives to natural growth factors, to reduce costs, improve consistency, and enhance performance in cell culture and regenerative medicine. Synthetic peptides are chemically engineered amino acid sequences designed to mimic the biological activity of natural FGFs by binding to the same receptors and activating key cellular signaling pathways. This approach ensures reliable long-term cell proliferation, improves stability, and enables precise receptor-specific activation. For instance, in October 2024, PeptiGrowth Inc., a Japan-based biotechnology company, introduced PG-011, a synthetic FGFR1c agonist peptide developed to replace natural FGF2 for stem cell cultivation and other rapidly dividing cell types. PG-011 features a chemically defined, animal-component-free composition, provides greater stability than recombinant proteins, and efficiently activates receptors even at lower concentrations. These advantages improve cost control, ensure consistent quality, and enhance scalability for research and emerging cell-based applications.

In September 2023, Kriya Therapeutics Inc., a US-based biopharmaceutical company, acquired Tramontane Therapeutics, S.L. for an undisclosed amount. Through this acquisition, Kriya Therapeutics gains Tramontane’s proprietary portfolio of Fibroblast Growth Factor 21 (FGF21) assets, including an adeno-associated virus (AAV) vector engineered for sustained expression of native FGF21 protein. This acquisition strengthens Kriya’s capabilities in treating metabolic diseases and enhances its gene therapy pipeline with a potential one-time therapy for Nonalcoholic Steatohepatitis (NASH). Tramontane Therapeutics S.L. is a Spain-based private gene therapy company founded on scientific expertise from Barcelona, specializing in metabolic and neurodegenerative disorders.

Major companies operating in the fibroblast growth factors (fgfs) market are Merck & Co. Inc., Thermo Fisher Scientific Inc., FUJIFILM Wako Pure Chemical Corporation, Lonza Group AG, Miltenyi Biotec B.V. & Co. KG, GenScript Biotech Corporation, 89bio Inc., R&D Systems Inc., ACROBiosystems Co. Ltd., Elabscience Biotechnology Inc., Cell Signaling Technology Inc., Proteintech Group Inc., Akero Therapeutics Inc., MedChemExpress LLC, Defined Bioscience Inc., Gold Biotechnology Inc. (GoldBio), Nucleus Biologics LLC, ZellBio GmbH, Affinity Biosciences Ltd.

North America was the largest region in the fibroblast growth factors (FGFs) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fibroblast growth factors (fgfs) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the fibroblast growth factors (fgfs) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the fibroblast growth factors market by increasing costs of imported bioreactors, purification systems, recombinant protein reagents, analytical instruments, and cold-storage logistics. Pharmaceutical and biotechnology companies in North America and Europe are most affected due to reliance on specialized imported bioprocessing equipment, while Asia-Pacific faces higher costs in exporting fgf-based therapeutics. These tariffs are raising production costs and slowing scale-up timelines. However, they are also promoting domestic biologics manufacturing, regional supplier partnerships, and investments in localized recombinant protein production infrastructure.

The fibroblast growth factors (fgfs) market research report is one of a series of new reports that provides fibroblast growth factors (fgfs) market statistics, including fibroblast growth factors (fgfs) industry global market size, regional shares, competitors with a fibroblast growth factors (fgfs) market share, detailed fibroblast growth factors (fgfs) market segments, market trends and opportunities, and any further data you may need to thrive in the fibroblast growth factors (fgfs) industry. This fibroblast growth factors (fgfs) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Fibroblast growth factors (FGFs) are a group of signaling proteins that play a vital role in cell proliferation, tissue repair, and development. They primarily promote fibroblast growth and differentiation, supporting wound healing and embryonic development. Additionally, FGFs regulate angiogenesis and influence various metabolic processes.

The primary product types of fibroblast growth factors (FGFs) include recombinant fibroblast growth factor, purified fibroblast growth factor, endogenous fibroblast growth factor, and others. Recombinant fibroblast growth factor is a laboratory-produced protein created through genetic engineering to generate large quantities for therapeutic and research applications. It is categorized into types such as palifermin, erdafitinib, infigratinib, futibatinib, and others. FGFs are applied in multiple fields, including oncology, hematology, wound healing, dermatology, cardiovascular diseases, bone disorders, musculoskeletal disorders, and tissue regeneration. They serve key end users such as pharmaceutical companies, research institutes, biotechnology firms, and others.

The fibroblast growth factors (FGFs) market consists of sales of fibroblast growth factors (FGFs)-based therapeutic proteins, growth factor supplements for cell culture, and related biologics used in wound healing, tissue regeneration, and cosmetic applications. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.